DK3533792T3 - Krystallinske former af en androgenreceptormodulator - Google Patents

Krystallinske former af en androgenreceptormodulator Download PDF

Info

Publication number: DK3533792T3
Authority: DK; Denmark
Prior art keywords: crystallinic; forms; androgen receptor; receptor modulator; modulator
Prior art date: 2012-06-07

Application number

DK19169275.5T

Other languages

English (en)

Inventor

Anna Dilhas

Ouathek Ouerfelli

Nicholas D Smith

Mark R Herbert

Original Assignee

Aragon Pharmaceuticals Inc

Sloan Kettering Inst Cancer Res

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2012-06-07

Filing date

2013-06-04

Publication date

2021-06-28

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=49712550&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK3533792(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2013-06-04 Application filed by Aragon Pharmaceuticals Inc, Sloan Kettering Inst Cancer Res filed Critical Aragon Pharmaceuticals Inc

2021-06-28 Application granted granted Critical

2021-06-28 Publication of DK3533792T3 publication Critical patent/DK3533792T3/da

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/28—Antiandrogens
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Epidemiology (AREA)
Endocrinology (AREA)
Diabetes (AREA)
Reproductive Health (AREA)
Urology & Nephrology (AREA)
Tropical Medicine & Parasitology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Medicinal Preparation (AREA)

DK19169275.5T 2012-06-07 2013-06-04 Krystallinske former af en androgenreceptormodulator DK3533792T3 (da)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US201261656888P	2012-06-07	2012-06-07
EP18157435.1A EP3348553B1 (en)	2012-06-07	2013-06-04	Crystalline forms of an androgen receptor modulator

Publications (1)

Publication Number	Publication Date
DK3533792T3 true DK3533792T3 (da)	2021-06-28

Family

ID=49712550

Family Applications (3)

Application Number	Title	Priority Date	Filing Date
DK18157435.1T DK3348553T3 (da)	2012-06-07	2013-06-04	Krystallinske former af en androgen receptormodulator
DK13800681.2T DK2858985T3 (da)	2012-06-07	2013-06-04	Krystallinske former af en androgen receptormodulator
DK19169275.5T DK3533792T3 (da)	2012-06-07	2013-06-04	Krystallinske former af en androgenreceptormodulator

Family Applications Before (2)

Application Number	Title	Priority Date	Filing Date
DK18157435.1T DK3348553T3 (da)	2012-06-07	2013-06-04	Krystallinske former af en androgen receptormodulator
DK13800681.2T DK2858985T3 (da)	2012-06-07	2013-06-04	Krystallinske former af en androgen receptormodulator

Country Status (45)

Country	Link
US (9)	US9481663B2 (da)
EP (4)	EP3348553B1 (da)
JP (3)	JP6182209B2 (da)
KR (2)	KR102062024B1 (da)
CN (3)	CN113135892A (da)
AU (3)	AU2013271751B2 (da)
BR (1)	BR112014030678A2 (da)
CA (4)	CA3055660A1 (da)
CL (1)	CL2014003331A1 (da)
CO (1)	CO7240407A2 (da)
CR (2)	CR20190331A (da)
CY (4)	CY1120393T1 (da)
DK (3)	DK3348553T3 (da)
EA (3)	EA201992010A1 (da)
EC (1)	ECSP14030098A (da)
ES (3)	ES2670683T3 (da)
FR (1)	FR21C1050I2 (da)
GT (1)	GT201400283A (da)
HK (2)	HK1210175A1 (da)
HR (3)	HRP20180902T1 (da)
HU (4)	HUE054595T2 (da)
IL (5)	IL320522A (da)
IN (1)	IN2014DN10084A (da)
LT (4)	LT3533792T (da)
LU (1)	LUC00236I2 (da)
ME (2)	ME03081B (da)
MX (1)	MX356754B (da)
MY (1)	MY187500A (da)
NI (1)	NI201400142A (da)
NL (1)	NL301144I2 (da)
NO (1)	NO2021046I1 (da)
NZ (2)	NZ717683A (da)
PE (3)	PE20150631A1 (da)
PH (2)	PH12014502714B1 (da)
PL (3)	PL2858985T3 (da)
PT (3)	PT2858985T (da)
RS (3)	RS60617B1 (da)
SG (3)	SG11201408140QA (da)
SI (3)	SI2858985T1 (da)
SM (3)	SMT201800311T1 (da)
TR (1)	TR201808939T4 (da)
TW (1)	TWI532732B (da)
UA (2)	UA123142C2 (da)
WO (1)	WO2013184681A1 (da)
ZA (1)	ZA201500076B (da)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US8461343B2 (en)	2007-03-27	2013-06-11	Sloan-Kettering Institute For Cancer Research	Synthesis of thiohydantoins
AU2012353660A1 (en)	2011-12-16	2014-06-12	Olema Pharmaceuticals, Inc.	Novel benzopyran compounds, compositions and uses thereof
KR102062024B1 (ko)	2012-06-07	2020-01-03	아라곤 파마슈티컬스, 인코포레이티드	안드로겐 수용체 조절제의 결정 형태
IN2015DN02875A (da)	2012-09-11	2015-09-11	Medivation Prostate Therapeutics Inc
ES2836424T3 (es)	2012-09-26	2021-06-25	Aragon Pharmaceuticals Inc	Antiandrógenos para tratar el cáncer de próstata no metastásico y resistente a la castración
JOP20200097A1 (ar)	2013-01-15	2017-06-16	Aragon Pharmaceuticals Inc	معدل مستقبل أندروجين واستخداماته
WO2016029776A1 (en) *	2014-08-26	2016-03-03	Astar Biotech Llc	Protein kinase inhibitors
EP3842034B1 (en)	2014-12-05	2025-02-12	Aragon Pharmaceuticals, Inc.	Anticancer compositions
RS66323B1 (sr)	2014-12-05	2025-01-31	Aragon Pharmaceuticals Inc	Sastavi protiv raka
EA201791251A1 (ru)	2014-12-05	2017-11-30	Арагон Фармасьютикалз, Инк.	Противораковые композиции
EP3235345B1 (en)	2014-12-19	2024-03-06	Lutron Technology Company LLC	Multi-channel lighting fixture having multiple light-emitting diode drivers
MX2018014846A (es)	2016-06-03	2019-03-14	Aragon Pharmaceuticals Inc	Composiciones antineoplasicas.
RU2019121700A (ru)	2016-12-13	2021-01-15	Ватсон Лэборетериз Инк.	Твердые формы апалутамида
US10702508B2 (en)	2017-10-16	2020-07-07	Aragon Pharmaceuticals, Inc.	Anti-androgens for the treatment of non-metastatic castration-resistant prostate cancer
WO2019135254A1 (en)	2018-01-02	2019-07-11	Mylan Laboratories Limited	Apalutamide polymorphs and their preparation thereof
EP3812378A1 (en) *	2018-06-20	2021-04-28	Crystal Pharmaceutical (Suzhou) Co., Ltd.	Crystal form of arn-509, preparation method therefor and use thereof
WO2020049598A2 (en)	2018-09-08	2020-03-12	Cipla Limited	Apalutamide polymorphs
IT201900003839A1 (it)	2019-03-15	2020-09-15	Olon Spa	Sintesi di apalutamide amorfa stabile
WO2020234817A1 (en) *	2019-05-21	2020-11-26	Laurus Labs Limited	Polymorphic forms of apalutamide and its preparation thereof
IT201900010593A1 (it)	2019-07-01	2021-01-01	Dipharma Francis Srl	Forma cristallina di un inibitore di recettori degli androgeni
EP4017848A1 (en) *	2019-08-22	2022-06-29	Dr. Reddy's Laboratories Ltd.	Process for the preparation of apalutamide
IT201900015974A1 (it)	2019-09-10	2021-03-10	Olon Spa	Apalutamide cristallina stabile in forma pura e processo per la sua preparazione
CN110590740A (zh) *	2019-09-20	2019-12-20	武汉大学	一种阿帕鲁胺化合物及其药物制剂
EP4541786A3 (en)	2020-09-04	2025-08-06	Synthon B.V.	Improved process for preparation of apalutamide
CN112679468A (zh) *	2021-01-05	2021-04-20	四川科伦药物研究院有限公司	阿帕他胺的晶体形式、制备方法和用途
WO2023143090A1 (zh) *	2022-01-25	2023-08-03	成都苑东生物制药股份有限公司	一种阿帕他胺溶剂化物新晶型及其制备方法
CN115536634B (zh) *	2022-10-17	2024-06-11	上海博悦生物科技有限公司	一种阿帕他胺的合成方法
CN116332907A (zh) *	2023-03-16	2023-06-27	奥锐特药业股份有限公司	一种无定形阿帕他胺的制备方法
WO2025153768A1 (en) *	2024-01-18	2025-07-24	Nanoform Finland Oyj	Composition comprising crystalline nanosized apalutamide

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5323907A (en)	1992-06-23	1994-06-28	Multi-Comp, Inc.	Child resistant package assembly for dispensing pharmaceutical medications
US7709517B2 (en) *	2005-05-13	2010-05-04	The Regents Of The University Of California	Diarylhydantoin compounds
CN101032483B (zh) *	2006-03-09	2011-05-04	陈德桂	调节雄激素受体活性的乙内酰脲衍生物及其应用
DK3100727T3 (da)	2006-03-27	2018-11-12	Univ California	Androgenreceptormodulator til behandling af prostatacancer og androgenreceptor-associerede sygdomme
US8110594B2 (en) *	2006-03-29	2012-02-07	The Regents Of The University Of California	Diarylthiohydantoin compounds
US8461343B2 (en)	2007-03-27	2013-06-11	Sloan-Kettering Institute For Cancer Research	Synthesis of thiohydantoins
PH12012501652A1 (en) *	2010-02-16	2012-10-22	Aragon Pharmaceuticals Inc	Androgen receptor modulators and uses thereof
KR102062024B1 (ko) *	2012-06-07	2020-01-03	아라곤 파마슈티컬스, 인코포레이티드	안드로겐 수용체 조절제의 결정 형태
EP3812378A1 (en)	2018-06-20	2021-04-28	Crystal Pharmaceutical (Suzhou) Co., Ltd.	Crystal form of arn-509, preparation method therefor and use thereof

2013
- 2013-06-04 KR KR1020157000266A patent/KR102062024B1/ko active Active
- 2013-06-04 NZ NZ717683A patent/NZ717683A/en unknown
- 2013-06-04 EA EA201992010A patent/EA201992010A1/ru unknown
- 2013-06-04 SM SM20180311T patent/SMT201800311T1/it unknown
- 2013-06-04 US US14/406,520 patent/US9481663B2/en active Active
- 2013-06-04 CN CN202110417935.XA patent/CN113135892A/zh active Pending
- 2013-06-04 DK DK18157435.1T patent/DK3348553T3/da active
- 2013-06-04 IL IL320522A patent/IL320522A/en unknown
- 2013-06-04 MX MX2014015005A patent/MX356754B/es active IP Right Grant
- 2013-06-04 CN CN201610202980.2A patent/CN105693692A/zh active Pending
- 2013-06-04 ES ES13800681.2T patent/ES2670683T3/es active Active
- 2013-06-04 LT LTEP19169275.5T patent/LT3533792T/lt unknown
- 2013-06-04 PE PE2014002383A patent/PE20150631A1/es active IP Right Grant
- 2013-06-04 UA UAA201702779A patent/UA123142C2/uk unknown
- 2013-06-04 LT LTEP13800681.2T patent/LT2858985T/lt unknown
- 2013-06-04 EP EP18157435.1A patent/EP3348553B1/en not_active Revoked
- 2013-06-04 HU HUE19169275A patent/HUE054595T2/hu unknown
- 2013-06-04 TR TR2018/08939T patent/TR201808939T4/tr unknown
- 2013-06-04 SI SI201331010T patent/SI2858985T1/sl unknown
- 2013-06-04 SG SG11201408140QA patent/SG11201408140QA/en unknown
- 2013-06-04 IN IN10084DEN2014 patent/IN2014DN10084A/en unknown
- 2013-06-04 SG SG10201610249TA patent/SG10201610249TA/en unknown
- 2013-06-04 CR CR20190331A patent/CR20190331A/es unknown
- 2013-06-04 CA CA3055660A patent/CA3055660A1/en not_active Abandoned
- 2013-06-04 CN CN201380041652.3A patent/CN104619692A/zh active Pending
- 2013-06-04 DK DK13800681.2T patent/DK2858985T3/da active
- 2013-06-04 RS RS20200913A patent/RS60617B1/sr unknown
- 2013-06-04 AU AU2013271751A patent/AU2013271751B2/en active Active
- 2013-06-04 SM SM20210355T patent/SMT202100355T1/it unknown
- 2013-06-04 EA EA201492272A patent/EA028791B1/ru unknown
- 2013-06-04 PL PL13800681T patent/PL2858985T3/pl unknown
- 2013-06-04 PL PL19169275T patent/PL3533792T3/pl unknown
- 2013-06-04 PE PE2020000234A patent/PE20200795A1/es unknown
- 2013-06-04 EP EP19169275.5A patent/EP3533792B1/en active Active
- 2013-06-04 TW TW102119817A patent/TWI532732B/zh active
- 2013-06-04 PT PT138006812T patent/PT2858985T/pt unknown
- 2013-06-04 CA CA3008345A patent/CA3008345C/en active Active
- 2013-06-04 ES ES18157435T patent/ES2809738T3/es active Active
- 2013-06-04 JP JP2015516121A patent/JP6182209B2/ja active Active
- 2013-06-04 DK DK19169275.5T patent/DK3533792T3/da active
- 2013-06-04 HU HUE13800681A patent/HUE038082T2/hu unknown
- 2013-06-04 SI SI201331788T patent/SI3348553T1/sl unknown
- 2013-06-04 EA EA201791592A patent/EA033956B1/ru unknown
- 2013-06-04 SM SM20200496T patent/SMT202000496T1/it unknown
- 2013-06-04 KR KR1020197033592A patent/KR102195916B1/ko active Active
- 2013-06-04 EP EP21171579.2A patent/EP3922629A1/en active Pending
- 2013-06-04 ME MEP-2018-158A patent/ME03081B/me unknown
- 2013-06-04 SG SG10201610248SA patent/SG10201610248SA/en unknown
- 2013-06-04 LT LTEP18157435.1T patent/LT3348553T/lt unknown
- 2013-06-04 PE PE2019002096A patent/PE20200725A1/es unknown
- 2013-06-04 CA CA3114726A patent/CA3114726A1/en active Pending
- 2013-06-04 HU HUE18157435A patent/HUE050357T2/hu unknown
- 2013-06-04 RS RS20180680A patent/RS57370B1/sr unknown
- 2013-06-04 HK HK15111086.5A patent/HK1210175A1/xx unknown
- 2013-06-04 SI SI201331894T patent/SI3533792T1/sl unknown
- 2013-06-04 PL PL18157435T patent/PL3348553T3/pl unknown
- 2013-06-04 PT PT191692755T patent/PT3533792T/pt unknown
- 2013-06-04 UA UAA201500086A patent/UA115665C2/uk unknown
- 2013-06-04 HR HRP20180902TT patent/HRP20180902T1/hr unknown
- 2013-06-04 ES ES19169275T patent/ES2875932T3/es active Active
- 2013-06-04 WO PCT/US2013/044116 patent/WO2013184681A1/en not_active Ceased
- 2013-06-04 RS RS20210739A patent/RS61988B1/sr unknown
- 2013-06-04 PT PT181574351T patent/PT3348553T/pt unknown
- 2013-06-04 CA CA2875767A patent/CA2875767C/en active Active
- 2013-06-04 NZ NZ702203A patent/NZ702203A/en unknown
- 2013-06-04 BR BR112014030678A patent/BR112014030678A2/pt not_active Application Discontinuation
- 2013-06-04 ME MEP-2020-163A patent/ME03815B/me unknown
- 2013-06-04 EP EP13800681.2A patent/EP2858985B1/en active Active
- 2013-06-04 MY MYPI2014703627A patent/MY187500A/en unknown
2014
- 2014-12-01 CR CR20140549A patent/CR20140549A/es unknown
- 2014-12-04 NI NI201400142A patent/NI201400142A/es unknown
- 2014-12-04 PH PH12014502714A patent/PH12014502714B1/en unknown
- 2014-12-04 IL IL236055A patent/IL236055A0/en unknown
- 2014-12-05 GT GT201400283A patent/GT201400283A/es unknown
- 2014-12-05 EC ECIEPI201430098A patent/ECSP14030098A/es unknown
- 2014-12-05 CL CL2014003331A patent/CL2014003331A1/es unknown
- 2014-12-09 CO CO14270612A patent/CO7240407A2/es unknown
2015
- 2015-01-06 ZA ZA2015/00076A patent/ZA201500076B/en unknown
2016
- 2016-07-26 PH PH12016501470A patent/PH12016501470B1/en unknown
- 2016-09-12 US US15/262,522 patent/US9994545B2/en active Active
- 2016-12-19 HK HK16114389.2A patent/HK1226066A1/zh unknown
2017
- 2017-01-17 AU AU2017200298A patent/AU2017200298B2/en active Active
- 2017-02-15 JP JP2017025746A patent/JP6345821B2/ja active Active
- 2017-12-22 AU AU2017279807A patent/AU2017279807B2/en active Active
2018
- 2018-05-09 US US15/975,449 patent/US10308630B2/en active Active
- 2018-05-23 JP JP2018098638A patent/JP2018141009A/ja active Pending
- 2018-05-31 IL IL259738A patent/IL259738B/en active IP Right Grant
- 2018-07-06 CY CY20181100712T patent/CY1120393T1/el unknown
2019
- 2019-04-15 US US16/384,002 patent/US10526310B2/en active Active
- 2019-06-24 IL IL267608A patent/IL267608B2/en unknown
- 2019-07-10 US US16/507,780 patent/US10556882B2/en active Active
- 2019-12-11 US US16/710,785 patent/US10766875B2/en active Active
2020
- 2020-06-15 IL IL275413A patent/IL275413A/en unknown
- 2020-07-29 US US16/942,069 patent/US10934271B2/en active Active
- 2020-08-31 HR HRP20201387TT patent/HRP20201387T1/hr unknown
- 2020-09-23 CY CY20201100901T patent/CY1123427T1/el unknown
2021
- 2021-01-26 US US17/158,806 patent/US12018008B2/en active Active
- 2021-06-08 HR HRP20210909TT patent/HRP20210909T1/hr unknown
- 2021-07-02 CY CY20211100595T patent/CY1124831T1/el unknown
- 2021-11-02 LU LU00236C patent/LUC00236I2/fr unknown
- 2021-11-02 NO NO2021046C patent/NO2021046I1/no unknown
- 2021-11-03 LT LTPA2021525C patent/LTC3533792I2/lt unknown
- 2021-11-03 NL NL301144C patent/NL301144I2/nl unknown
- 2021-11-03 FR FR21C1050C patent/FR21C1050I2/fr active Active
- 2021-11-04 CY CY2021032C patent/CY2021032I2/el unknown
- 2021-11-04 HU HUS2100047C patent/HUS2100047I1/hu unknown
2024
- 2024-05-13 US US18/662,345 patent/US20250092011A1/en not_active Abandoned

Also Published As

Publication number	Publication date
AU2013271751A1 (en)	2014-12-18
PE20200725A1 (es)	2020-07-21
CY2021032I2 (el)	2022-03-24
AU2017200298B2 (en)	2017-09-28
NZ702203A (en)	2016-09-30
CA2875767A1 (en)	2013-12-12
KR102195916B1 (ko)	2020-12-30
CN113135892A (zh)	2021-07-20
EP2858985A1 (en)	2015-04-15
IL267608A (en)	2019-08-29
IN2014DN10084A (da)	2015-08-21
LUC00236I2 (da)	2025-02-03
RS61988B1 (sr)	2021-07-30
EP2858985B1 (en)	2018-04-18
IL259738A (en)	2018-07-31
UA115665C2 (uk)	2017-12-11
TR201808939T4 (tr)	2018-07-23
LT3533792T (lt)	2021-07-26
IL275413A (en)	2020-07-30
US20210163441A1 (en)	2021-06-03
EP3533792B1 (en)	2021-05-05
NL301144I2 (nl)	2025-03-20
CN105693692A (zh)	2016-06-22
IL236055A0 (en)	2015-02-01
US20170001977A1 (en)	2017-01-05
IL267608B2 (en)	2025-10-01
PH12016501470A1 (en)	2017-07-10
CO7240407A2 (es)	2015-04-17
US10766875B2 (en)	2020-09-08
EA201992010A1 (ru)	2020-01-24
HK1226066A1 (zh)	2017-09-22
US10556882B2 (en)	2020-02-11
HRP20210909T1 (hr)	2021-09-03
LTC3533792I2 (da)	2024-07-10
US10308630B2 (en)	2019-06-04
HUE038082T2 (hu)	2018-09-28
MX2014015005A (es)	2015-09-04
LT2858985T (lt)	2018-09-25
EP3922629A1 (en)	2021-12-15
SMT202100355T1 (it)	2021-07-12
EA201492272A1 (ru)	2015-05-29
EA028791B1 (ru)	2017-12-29
NZ717683A (en)	2018-04-27
JP2018141009A (ja)	2018-09-13
FR21C1050I2 (fr)	2024-05-24
AU2013271751B2 (en)	2017-02-23
ES2670683T3 (es)	2018-05-31
EP2858985A4 (en)	2016-05-25
ME03815B (me)	2021-04-20
US9481663B2 (en)	2016-11-01
AU2017279807A1 (en)	2018-01-25
CY1123427T1 (el)	2021-12-31
JP6345821B2 (ja)	2018-06-20
UA123142C2 (uk)	2021-02-24
ME03081B (me)	2019-01-20
SMT201800311T1 (it)	2018-07-17
SG11201408140QA (en)	2015-01-29
US12018008B2 (en)	2024-06-25
CA2875767C (en)	2018-08-14
IL320522A (en)	2025-06-01
US20250092011A1 (en)	2025-03-20
LTPA2021525I1 (da)	2021-11-25
PT2858985T (pt)	2018-07-10
EA201791592A1 (ru)	2018-01-31
CA3008345C (en)	2019-10-22
EP3348553B1 (en)	2020-07-08
JP2015518890A (ja)	2015-07-06
TW201402561A (zh)	2014-01-16
LT3348553T (lt)	2020-09-25
NO2021046I1 (no)	2021-11-02
BR112014030678A2 (pt)	2017-06-27
PE20150631A1 (es)	2015-05-11
US20190330182A1 (en)	2019-10-31
SI3348553T1 (sl)	2020-11-30
US20150133481A1 (en)	2015-05-14
US20200115361A1 (en)	2020-04-16
CL2014003331A1 (es)	2016-03-04
CY1124831T1 (el)	2022-03-24
GT201400283A (es)	2017-07-03
CN104619692A (zh)	2015-05-13
DK3348553T3 (da)	2020-07-27
PL3348553T3 (pl)	2021-02-08
JP2017178923A (ja)	2017-10-05
US10526310B2 (en)	2020-01-07
ES2875932T3 (es)	2021-11-11
CR20140549A (es)	2015-04-06
SI2858985T1 (sl)	2018-12-31
RS57370B1 (sr)	2018-08-31
KR102062024B1 (ko)	2020-01-03
SMT202000496T1 (it)	2020-11-10
US9994545B2 (en)	2018-06-12
CY2021032I1 (da)	2022-03-24
PT3348553T (pt)	2020-09-28
SG10201610249TA (en)	2017-02-27
MY187500A (en)	2021-09-24
JP6182209B2 (ja)	2017-08-16
US20200354335A1 (en)	2020-11-12
CA3055660A1 (en)	2013-12-12
ES2809738T3 (es)	2021-03-05
PT3533792T (pt)	2021-06-07
AU2017279807B2 (en)	2018-11-08
IL267608B1 (en)	2025-06-01
HK1210175A1 (en)	2016-04-15
US20190241539A1 (en)	2019-08-08
MX356754B (es)	2018-06-11
EP3348553A1 (en)	2018-07-18
ZA201500076B (en)	2016-10-26
DK2858985T3 (da)	2018-05-28
TWI532732B (zh)	2016-05-11
CR20190331A (es)	2019-11-12
HUE054595T2 (hu)	2021-09-28
HRP20201387T1 (hr)	2020-11-27
EP3533792A1 (en)	2019-09-04
WO2013184681A1 (en)	2013-12-12
HRP20180902T1 (hr)	2018-08-24
HUS2100047I1 (hu)	2021-11-29
ECSP14030098A (es)	2016-01-29
CA3114726A1 (en)	2013-12-12
PL2858985T3 (pl)	2018-09-28
PH12014502714A1 (en)	2015-02-02
KR20150021993A (ko)	2015-03-03
HUE050357T2 (hu)	2020-11-30
PH12014502714B1 (en)	2015-02-02
PE20200795A1 (es)	2020-08-10
CA3008345A1 (en)	2013-12-12
AU2017200298A1 (en)	2017-02-02
KR20190132543A (ko)	2019-11-27
IL259738B (en)	2021-06-30
RS60617B1 (sr)	2020-09-30
PL3533792T3 (pl)	2021-11-29
FR21C1050I1 (fr)	2021-12-10
SI3533792T1 (sl)	2021-11-30
EA033956B1 (ru)	2019-12-13
US20180258067A1 (en)	2018-09-13
NI201400142A (es)	2016-12-02
US10934271B2 (en)	2021-03-02
PH12016501470B1 (en)	2021-12-10
CY1120393T1 (el)	2019-07-10
SG10201610248SA (en)	2017-02-27

Publication	Publication Date	Title
CY2021032I2 (el)	2022-03-24	Κρυσταλλiκες μορφες διαμορφωτη υποδοχεα ανδρογονων
DK2906696T4 (da)	2023-02-27	Fremgangsmåder til modulering af c9orf72-ekspression
DK3087183T3 (da)	2020-09-14	Modulation af angiopoietin-3-lignende ekspression
DK3461895T3 (da)	2020-07-20	Modulation af ube3a-ats-ekspression
DK3454346T3 (da)	2021-11-01	Anordning til cylotronfremstilling af technetium-99m
DK3074011T3 (da)	2019-09-30	Octahydro-kondenserede azadecalin-glucocorticoidreceptormodulatorer
DK3235824T3 (da)	2019-05-20	Blanding af rp/sp gemcitabin-[phenyl-(benzyloxy-l-alaninyl)]-phosphat
DK3456831T3 (da)	2021-09-06	Målrettet modifikation af rottegenom
EP2906226A4 (en)	2016-06-08	MODULATION OF ANDROGEN RECEPTOR EXPRESSION
HUE042443T2 (hu)	2019-06-28	GPR6 tetrahidropiridopirazin-modulátorai
EP2911666A4 (en)	2016-10-12	MODULATORS OF A RESISTANT ANDROGEN RECEPTOR
SMT201700009B (it)	2017-03-08	Modulatori del recettore x del fegato
DK2965026T3 (da)	2019-10-28	Generering af slushice
SMT201600374B (it)	2016-11-10	Modulatori del recettore x del fegato
DK2919777T3 (da)	2020-03-09	Transmukosal afgivelse af tocotrienol
IL231440A0 (en)	2014-04-30	Selective androgen receptor modulators
DK2894998T3 (da)	2020-03-02	Rotation af kegle
ME02996B (me)	2018-10-20	Indolkarb0niтrili као selekтivni modulatori receptora androgena
DK2888228T3 (da)	2019-07-15	Inhibitorer af CD40-TRAF6 interaktion
DK2844623T3 (da)	2019-07-15	Fremgangsmåder til fremstilling af perlitholdige byggematerialer
DK2928896T3 (da)	2017-11-06	Fast form af dihydro-pyrido-oxazin-derivat
DK2901162T3 (da)	2019-06-24	Fremgangsmåde til diagnosticering af muskeldystrofi
DK2651028T3 (da)	2019-05-13	Vurdering af fortandingsmoment
TH1401007292A (th)	2016-09-20	รูปแบบผลึกของแอนโดรเจนรีเซปเตอร์มอดูเลเตอร์